Now more than ever, pharmaceutical and life science companies need product and process-level risk management across development, manufacturing and distribution. And yet, as the pandemic, technology, and competitive disruptions persist, many CFOs struggle to gain control over the pharmaceutical lifecycle.
On top of managing a tumultuous industry, the office of the CFO has to plan, fund, and control the business while driving financial performance, managing the investor community, and ensuring compliance with tax and regulatory requirements.
In this webinar, CFO Outlook: Pharma CFOs look beyond profit to long term value, a panel of experts from EY and CCH® Tagetik come together to explore the unique challenges facing pharma’s office of the CFO and why the cure to all that ails them is a combination of long-term value creation, integrated drug lifecycle planning, and modernized technology.
Title:
CFO Outlook: Pharma CFOs look beyond profit to long term value
Speakers:
- Norman Emmenlauer, Partner, EY
- Fabrizio Tocchini, Global Head of Innovation, CCH Tagetik
Moderator:
- Martin Watson, Sales Director, CCH Tagetik